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Figure 1. Cytotoxic activity (mean and standard deviation) of lymphoid
leukemia-speciﬁc cord blood T cells expanded in cytokine cocktails IL-7, -12, &
- 15(n¼4) or IL-15 (n¼5) and IL-7 alone (n¼3)
Table 1
Dispose Reason N % of disposed
CBU/barcodes
(n¼77149)
Low TNCC 30815 39.9
Low Volume 17415 22.6
Placenta issue 7279 9.4
Not collected 5356 6.9
Maternal history problem 3817 4.9
Cord issue 3693 4.8
Low Viability 1404 1.8
Processing issues 1159 1.5
Cord clot 872 1.1
Maternal Sample Problem 750 1.0
Consent refused/withdrawn 567 0.7
Donate/research 553 0.7
Data Missing 546 0.7
Failed CBU Sterility 529 0.7
Subsequent Med Info 476 0.6
CBU Expired 364 0.5
Delivery complication 326 0.4
Training unit 307 0.4
Collection kit issue 301 0.4
Cryopreservation 251 0.3
Abnormality in baby 232 0.3
Potency/CFU 88 0.1
NRBC >50% 49 0.1
TOTAL 77149
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ated with IL-15 alone from previously CD3/CD28 expanded
CB T cells. While the cytotoxicity is comparable to those
primed/expanded by combinations of cytokines, the CTL
speciﬁcity is higher with IL-15 alone. Notably, the CTL activity
is not conﬁned to a single cellular subset and resides in the
TCRgd+ T cell.415
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Background: The goal of the Carolinas Cord Blood Bank
(CCBB), a public cord blood (CB) bank, is to procure quality
cord blood units (CBU) for use in hematopoietic stem cell
transplantation. The banking process is comprised of donor
screening, collection, processing, cryopreservation and
testing. At each step, CBU eligibility is determined and units
not meeting speciﬁcations are discarded. We explored
reasons for CBU disposal to identify strategies to maximize
the number of successfully banked CBUs.
Study design and methods: The CCBB database was retro-
spectively analyzed to characterize and quantify reasons
CBUs were ineligible for banking. The reasons for discard
were collated, assigned to a step on a process chain and
assigned to a category. Speciﬁcations for banking included
a minimum volume of 40ml (to 2005) and 60ml (to present),
a preprocessing total nucleated cell count (TNCC) of
1x109cells and a post processing viability of >90%.
Results: From 1/1998-8/2012, 109,177 total CBU donors
registered in the database. Of these, 34% did not have CBUs
collected because of unavailable collection staff, placental/
cord damage or CB clot, among other reasons. A total of
71,618 CBUs were collected, 40,986 (57%) of which were
shipped to the processing lab. Twenty-two percent of the
CBUs sent for processing were subsequently discarded. Time
points for discard of collected CBUs were: 43% before pro-
cessing, 5% during processing and 7% after cryopreservation.
Reasons for disposal of 77,149 registrations or CBUs (Table 1)
included 40% for low TNCC, 23% for low volume, 2% for low
viability, and 0.7% for failed sterility.
Conclusion: We identiﬁed reasons for banking failures in
a large public CB bank. While small volumes/low TNCC rep-
resented the major reasons for failure of collected CBUs to bebanked, other factors inﬂuenced the failure to collect CBUs
from recruited volunteer donors. Improving MD and tech-
nician training to increase the volume of collections and
awareness of collection procedures in regards to placenta
and cord handling, as well as expanding program collection
hours, could impact the overall banking success. The ﬁnan-
cial impact of CBU losses will also be discussed.
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Introduction: Bronchiolitis Obliterans Syndrome (BOS) is
the manifestation of chronic GVHD (cGVHD) of the lung, it
affects approximately 10% of patients surviving one year post
transplantation (2), and the survival at 5 years is only about
10% (3). A timely diagnosis could improve the outcome of
this potentially fatal disease.
Methods: Using a lung transplantation scoring system (4),
we retrospectively evaluated 23 consecutive BOS patients to
determine whether an FEV1<90% and FEF25-75<75% (stage
BOS 0p), would have contributed to earlier detection. Addi-
tionally, we assessed IGF-1 (insulin growth factor 1) levels,
a proﬁbrogenic mediator (1), in serum samples of patients at
onset of cGVHD (n¼57), including 13/23 patients with
a diagnosis of BOS. A retrospective chart review was per-
formed to identify patients meeting the NIH Consensus
clinical deﬁnition of chronic GVHD of the lung (BOS) between
2007 and 2011. The criteria included: 1) FEV1 < .8 2) FEV1/
FVC < .75 and RV> 120% and 3)no evidence of infection on
most recent imaging or BAL at time of diagnosis. The dates
